← All trials
NCT05052541
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Sep 22, 2021
- Last posted
- Sep 22, 2021
- Enrollment
- 157
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Colorado, DenverLead sponsor
- University of Colorado, DenverOverall official - principal investigator
- Colorado Department of Public Health and EnvironmentCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.